Fresh From the Bench: Latest Precedential Patent Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Honeywell International Inc. v. 3G Licensing, S.A., Appeal Nos. 2023-1354, -1384, -1407 (Fed. Cir. Jan. 2, 2025)
In this week’s Case of the Week, the Federal Circuit reversed an inter partes review finding of the Patent Trial and Appeal Board, which had upheld the patentability of challenged claims of appellee 3G Licensing’s U.S. Patent No. 7,319,718. The ’718 patent claimed transmission encoding methods essential to the 3G and 4G cellular communications standards, and was weighed against prior art that comprised 3G consortium members’ consideration of desirable standards shortly before the patent’s critical date. A majority of the reviewing panel found the challenged claims reflected no more than routine experimentation and optimization of a proposal that had been circulated prior to the patent’s filing, and were therefore unpatentable as obvious.
Broadly speaking, the ’718 patent claimed a method of reducing errors in the transmission of channel quality information (CQI), a metric that had been used in cellular communications services to inform the allocation of bandwidth. The ’718 patent’s claims were directed to encoding the five-bit CQI into a 20-bit “codeword,” using conversion methods that redundantly repeated certain bits of the CQI to compensate for transmission errors.
Editors:
Nika Aldrich, IP Litigation Group Leader, Schwabe
Jason A. Wrubleski, Shareholder
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…